Literature DB >> 8971077

The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined.

V Gupta1, D C Wahoff, D P Rooney, V Poitout, D E Sutherland, D M Kendall, R P Robertson.   

Abstract

The optimal site for pancreatic islet cell transplantation is presently unclear, although the liver has been the most commonly used. However, glucagon secretion from islets that have been autotransplanted in liver has been reported to be unresponsive to hypoglycemia yet responsive to arginine. To determine whether this selective glucagon secretory defect is related to the intrahepatic site of islet implantation or to the process of transplantation per se, we studied counterregulatory responses to hypoglycemia in dogs with pancreatic islet autotransplantation in the hepatic parenchyma (the intrahepatic [IH] group, n = 9) or the peritoneal cavity (the intraperitoneal [IP] group, n = 9), following total pancreatectomy, and compared them with the responses in normal controls (n = 10). Dogs were subjected to a hypoglycemic hyperinsulinemic (5 mU x kg-1 x min-1) clamp for 90 min under general anesthesia. Arterial glucose concentrations were clamped at 2.7 mmol/l for the final 45 min of the clamp. Immediately following the clamp, glucagon responses to IV arginine (5 g) were also assessed. During hypoglycemia, glucagon responses in the IH group (maximal incremental glucagon = 33 +/- 21 ng/l; glucagon area under curve [AUC] = 713 +/- 1,022 ng x l-1 x min-1) were significantly lower than either the IP (maximal incremental glucagon = 92 +/- 32 ng/l; glucagon AUC = 4,090 +/- 1,600 ng x l-1 x min-1) or control (maximal incremental glucagon = 154 +/- 71 ng/l; glucagon AUC = 6,943 +/- 2,842 ng x l-1 x min-1) group (IH vs. IP group, P < 0.05; control vs. IH group, P < 0.01). Glucagon responses in the IP group did not differ significantly from the control group. Epinephrine responses to hypoglycemia were similar in all groups, whereas neither of the transplanted groups (IH and IP) had pancreatic polypeptide responses. There was a prompt rise in plasma glucagon after intravenous arginine in all groups. These data indicate that glucagon unresponsiveness to hypoglycemia is specific to intrahepatically transplanted islets, rendering the liver a disadvantageous site for optimal alpha-cell function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8971077     DOI: 10.2337/diab.46.1.28

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  20 in total

1.  No islets left behind: islet autotransplantation for surgery-induced diabetes.

Authors:  Melena D Bellin; A N Balamurugan; Timothy L Pruett; David E R Sutherland
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 2.  Assessment of islet function following islet and pancreas transplantation.

Authors:  Emily C Dy; David M Harlan; Kristina I Rother
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

Review 3.  Cellular therapies for type 1 diabetes.

Authors:  D D Lee; E Grossman; A S Chong
Journal:  Horm Metab Res       Date:  2008-02       Impact factor: 2.936

4.  Islet transplantation for type 1 diabetes, 2015: what have we learned from alloislet and autoislet successes?

Authors:  R Paul Robertson
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

Review 5.  Lessons learned from more than 1,000 pancreas transplants at a single institution.

Authors:  D E Sutherland; R W Gruessner; D L Dunn; A J Matas; A Humar; R Kandaswamy; S M Mauer; W R Kennedy; F C Goetz; R P Robertson; A C Gruessner; J S Najarian
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

Review 6.  Clinical islet transplantation.

Authors:  Dixon B Kaufman; William L Lowe
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

Review 7.  Islet transplantation a decade later and strategies for filling a half-full glass.

Authors:  R Paul Robertson
Journal:  Diabetes       Date:  2010-06       Impact factor: 9.461

Review 8.  Risks and side effects of islet transplantation.

Authors:  Edmond A Ryan; Breay W Paty; Peter A Senior; A M James Shapiro
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

9.  Defective glucagon secretion during hypoglycemia after intrahepatic but not nonhepatic islet autotransplantation.

Authors:  M D Bellin; S Parazzoli; E Oseid; L D Bogachus; C Schuetz; M E Patti; T Dunn; T Pruett; A N Balamurugan; B Hering; G Beilman; D E R Sutherland; R P Robertson
Journal:  Am J Transplant       Date:  2014-08       Impact factor: 8.086

Review 10.  Pancreas and islet cell transplantation.

Authors:  Rita Bottino; Massimo Trucco; A N Balamurugan; Thomas E Starzl
Journal:  Best Pract Res Clin Gastroenterol       Date:  2002-06       Impact factor: 3.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.